Deutsche Börse’s Eurex derivatives business has announced the appointments of Lee Bartholomew and Zubin Ramdarshan who have joined the company in key product development roles.
Zubin Ramdarshan has been appointed as the new Head of Derivatives Product R&D Equity and Index. He was previously at financial services firm Cantor Fitzgerald where he was a managing director for the European ETF business. Prior to this, he held senior-level roles at Jefferies, Macquarie Bank and Bear Stearns.
Lee Bartholomew is Eurex’ new Head of Derivatives Product R&D Fixed Income. He joins Deutsche Börse from Royal Bank of Canada, where he was responsible for developing the bank’s flow structured rates business. He previously held senior trading positions in structured rates at Lloyds Banking Group.
EuropeFX Partners with Acuity for AI-Powered News Sentiment AnalysisGo to article >>
Lee and Zubin bring with them a wealth of expertise, experience and market knowledge.
Commenting on the new appointments, Thomas Book, Eurex CEO and Head of Derivatives Markets Trading for Deutsche Börse Group, said: ”Lee and Zubin bring a wealth of expertise, experience and market knowledge to accelerate our development of new derivatives products at a particularly exciting time for the growth of this segment of the Deutsche Börse business.”
“These appointments underline Deutsche Börse’s strong commitment to high-quality product engineering and reinforce our capacity to meet customers’ evolving requirements in a challenging and fast-evolving regulatory and trading environment”, added Mehtap Dinc, member of the Eurex Executive Board, responsible for Global Derivatives Product Development at Deutsche Börse.
According to Deutsche Börse’s statement, Bartholomew and Ramdarshan have joined in the middle of an industry transformation that is challenging market infrastructure providers to constantly drive innovation and foster technical excellence in order to best serve the market’s needs. Despite the continued historic lows in European interest rates, Eurex’ index products have experienced strong growth across its MSCI and STOXX portfolios.